OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
24
Results
Show all
Save search
Copy query
Show results for
Unknown
(24)
Publication Date
Release Date
2021
(6)
2025
(5)
2024
(4)
2022
(3)
2023
(2)
2020
(2)
2016
(1)
2015
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Dexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595
|
biostudies-literature
Cite
Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial.
Not available
S-EPMC5443623
|
biostudies-literature
Cite
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Not available
S-EPMC5200636
|
biostudies-literature
Cite
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Not available
S-EPMC11408082
|
biostudies-literature
Cite
Sex Differences in Long COVID.
Not available
S-EPMC11755195
|
biostudies-literature
Cite
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338
|
biostudies-literature
Cite
Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.
Not available
S-EPMC12464792
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets